Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice

por Nakagawa, Tomoo, Kobayashi, Taku, Nishikawa, Kiyohiro, Yamada, Fumika, Asai, Satoshi, Sameshima, Yukinori, Suzuki, Yasuo, Watanabe, Mamoru, Hibi, Toshifumi
Publicado 2019

Treatment Result of the Mucopexy-Recto Anal Lifting Method for Hemorrhoids in Comparison with Ligation and Excision, and Aluminum Potassium Sulfate and Tannic Acid Sclerotherapy

por Sameshima, Takashi, Niwa, Kiyoshi, Eto, Tadaaki, Sameshima, Kanako, Ogata, Shunji, Yamamoto, Yuuko, Imamura, Yoshiro, Nishimata, Nobuaki, Hirakawa, Asami, Hamamoto, Hitomi, Sameshima, Yukinori
Publicado 2022

Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study

por Hibi, Toshifumi, Motoya, Satoshi, Ashida, Toshifumi, Sai, Souken, Sameshima, Yukinori, Nakamura, Shiro, Maemoto, Atsuo, Nii, Masahiro, Sullivan, Barbara A, Gasser Jr, Robert A., Suzuki, Yasuo
Publicado 2019

Infliximab therapy intensification based on endoscopic activity is related to suppress treatment discontinuation in patients with Crohn disease: A retrospective cohort study

por Komaki, Yuga, Kanmura, Shuji, Yutsudo, Kazuki, Kuwazuru, Kosuke, Komaki, Fukiko, Tanaka, Akihito, Nishimata, Nobuaki, Sameshima, Yoichi, Sasaki, Fumisato, Ohi, Hidehisa, Nakamura, Yuichi, Tokushige, Koichi, Sameshima, Yukinori, Ido, Akio
Publicado 2021